ReGen Biologics, Inc.

Cartilage regeneration

Founded in 1990, ReGen is headquartered in Franklin Lakes, New Jersey, and operates an ISO 9001 certified manufacturing facility in Redwood City, California. ReGen (OTC: RGBI) is an orthopaedic products company providing minimally invasive human implants and medical devices. Its primary product is the Collagen Meniscus Implant that has been approved for sale in Europe, Australia, Chile and certain other countries.

Gerald E. Bisbee, jr., PhD, President and CEO
John Dichiara, Senior VP, Clinical and Regulatory Affairs
William G. Rodkey, VP, Scientific Affairs
Brion D. Umidi, Senior VP and CFO

Gerald E. Bisbee, Jr., PhD, Chairman
Abhi Acharya, PhD
Alan W. Baldwin
Robert G. McNeil, PhD
Richard Steadman, MD
William R. Timken

Charles P. Ho, MD, PhD
Steven P. Arnoczky
Mininder S. Kocher, MD
Paolo Bulgheroni, MD
Juan Carlos Monllau, MD
Shu-Tung Li, PhD

411 Hackensack Avenue
Hackensack, NJ 07601
USA
Phone: +1-201-651-5140
Fax: +1-201-342-2288

ReGen’s research is based on the concept of guided tissue regeneration. ReGen’s flagship product, the CMI (Collagen Meniscus Implant), is focused in orthopaedics. CMI is a type I collagen implant designed for patients with an irreparable meniscus tear or loss of meniscus tissue.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.